Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy K Nevala

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2011
Differential response of human and mouse dendritic cells to VEGF determines interspecies discrepancies in tumor-mediated TH1/TH2 polarity shiftMatthew S Block, Wendy K Nevala, Alexey A Leontovich, et al.
Future Oncology (London, England)|November 15, 2012
Personalized therapy for metastatic melanoma: could timing be everything?Roxana S Dronca, Alexey A Leontovich, Wendy K Nevala, et al.
Frontiers in Immunology|September 18, 2015
Immune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer TherapeuticsElizabeth Ann L Enninga, Wendy K Nevala, Shernan G Holtan, et al.
International Journal of Molecular Sciences|April 17, 2025
PD-L1-Targeting Nanoparticles for the Treatment of Triple-Negative Breast Cancer: A Preclinical ModelWendy K Nevala, Liyi Geng, Hui Xie, et al.
Scientific Reports|November 5, 2017
Identification of a peptide-peptide binding motif in the coating of nab-paclitaxel nanoparticles with clinical antibodies: bevacizumab, rituximab, and trastuzumabJohn T Butterfield, Hidong Kim, Daniel J Knauer, et al.
Clinical & Developmental Immunology|March 16, 2011
Expansion of CD16-negative natural killer cells in the peripheral blood of patients with metastatic melanomaShernan G Holtan, Douglas J Creedon, Michael A Thompson, et al.
Scientific Reports|April 6, 2017
Antibody-targeted paclitaxel loaded nanoparticles for the treatment of CD20<sup>+</sup> B-cell lymphomaWendy K Nevala, John T Butterfield, Shari L Sutor, et al.
American Journal of Reproductive Immunology (New York, N.Y. : 1989)|August 6, 2014
Fetal sex-based differences in maternal hormones, angiogenic factors, and immune mediators during pregnancy and the postpartum periodElizabeth Ann L Enninga, Wendy K Nevala, Douglas J Creedon, et al.
Melanoma Research|July 26, 2016
Galectin-9 modulates immunity by promoting Th2/M2 differentiation and impacts survival in patients with metastatic melanomaElizabeth Ann L Enninga, Wendy K Nevala, Shernan G Holtan, et al.
Oncoimmunology|June 14, 2013
The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanomaAaron S Mansfield, Wendy K Nevala, Elizabeth Ann T Lieser, et al.
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2011
Differential response of human and mouse dendritic cells to VEGF determines interspecies discrepancies in tumor-mediated TH1/TH2 polarity shiftMatthew S Block, Wendy K Nevala, Alexey A Leontovich, et al.
Future Oncology (London, England)|November 15, 2012
Personalized therapy for metastatic melanoma: could timing be everything?Roxana S Dronca, Alexey A Leontovich, Wendy K Nevala, et al.
Frontiers in Immunology|September 18, 2015
Immune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer TherapeuticsElizabeth Ann L Enninga, Wendy K Nevala, Shernan G Holtan, et al.
International Journal of Molecular Sciences|April 17, 2025
PD-L1-Targeting Nanoparticles for the Treatment of Triple-Negative Breast Cancer: A Preclinical ModelWendy K Nevala, Liyi Geng, Hui Xie, et al.
Scientific Reports|November 5, 2017
Identification of a peptide-peptide binding motif in the coating of nab-paclitaxel nanoparticles with clinical antibodies: bevacizumab, rituximab, and trastuzumabJohn T Butterfield, Hidong Kim, Daniel J Knauer, et al.
Clinical & Developmental Immunology|March 16, 2011
Expansion of CD16-negative natural killer cells in the peripheral blood of patients with metastatic melanomaShernan G Holtan, Douglas J Creedon, Michael A Thompson, et al.
Scientific Reports|April 6, 2017
Antibody-targeted paclitaxel loaded nanoparticles for the treatment of CD20<sup>+</sup> B-cell lymphomaWendy K Nevala, John T Butterfield, Shari L Sutor, et al.
American Journal of Reproductive Immunology (New York, N.Y. : 1989)|August 6, 2014
Fetal sex-based differences in maternal hormones, angiogenic factors, and immune mediators during pregnancy and the postpartum periodElizabeth Ann L Enninga, Wendy K Nevala, Douglas J Creedon, et al.
Melanoma Research|July 26, 2016
Galectin-9 modulates immunity by promoting Th2/M2 differentiation and impacts survival in patients with metastatic melanomaElizabeth Ann L Enninga, Wendy K Nevala, Shernan G Holtan, et al.
Oncoimmunology|June 14, 2013
The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanomaAaron S Mansfield, Wendy K Nevala, Elizabeth Ann T Lieser, et al.
Pageof 6